世界のアルツハイマー病のパイプライン薬市場 2019年

【英語タイトル】Global Alzheimer's Pipeline Drugs Market Professional Survey Report 2019

QYResearchが出版した調査資料(QYR20FB00357)・商品コード:QYR20FB00357
・発行会社(調査会社):QYResearch
・発行日:2019年11月(※2024年版があります。お問い合わせください)
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,250 ⇒換算¥777,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートは、アルツハイマー病のパイプライン薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、Axura、ナメンダ、エビクサ、、アリセプト、ヌートロピル、イクセロン、メマリー、ソラネズマブ、LuAe58054に、用途別には、病院、ドラッグストアにセグメント区分し、アルツハイマー病のパイプライン薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・アルツハイマー病のパイプライン薬の世界市場概要
・アルツハイマー病のパイプライン薬の製造コスト構成分析
・アルツハイマー病のパイプライン薬の開発・製造工場分析
・主要メーカーの主な指標(生産能力、売上、価格分析)
・アルツハイマー病のパイプライン薬の地域別分析(生産、売上、主要メーカー、輸出・輸入)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・アルツハイマー病のパイプライン薬のセグメント分析(種類別)
(Axura、ナメンダ、エビクサ、、アリセプト、ヌートロピル、イクセロン、メマリー、ソラネズマブ、LuAe58054)
・アルツハイマー病のパイプライン薬のセグメント分析(用途別)
(病院、ドラッグストア)
・アルツハイマー病のパイプライン薬の主要メーカー別分析(生産拠点、製品概要、生産・売上実績)
(Forest Laboratorie、Eisai、H. Lundbeck A/S、Novartis、Merz GmbH & Co. KGaA、Johnson & Johnson、UCB)
・アルツハイマー病のパイプライン薬の市場規模予測(2019年~2025年)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス(市場動向、機会、成長要因、課題、影響因子)
...
【レポートの概要】

Alzheimer’s is a complex disease,though many marketed drugs have been approved for Alzheimer’s disease, but it still remains a significant area of unmet medical need. Currently there’s no cure for Alzheimer’s and its still waiting for its key product, numerous companies are developing novel treatments.For pharmaceutical companies which are developing targeted novel therapies, the current unmet needs represent a huge opportunity . If succeed, they will be in a position to command premium prices and tap the existing opportunity.
As the risk of getting the disease increases with age, the number of patients with the illness to be found in community will depend on the proportion of older people in the group.
Traditionally, the developed countries have large proportions of elderly people, and so they have many cases of Alzheimer’s disease in the community at one time. At the mean time, developing countries are also undergoing a demographic transition so that more and more persons are surviving to an old age.

The global Alzheimer’s Pipeline Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Alzheimer’s Pipeline Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alzheimer’s Pipeline Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Alzheimer’s Pipeline Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Alzheimer’s Pipeline Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Forest Laboratorie
Eisai
H. Lundbeck A/S
Novartis
Merz GmbH & Co. KGaA
Johnson & Johnson
UCB

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Namenda
Ebixa
Axura
Aricept
Nootropil
Exelon
Memary
Solanezumab
LuAe58054

Segment by Application
Hospital
Drug Store

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Alzheimer’s Pipeline Drugs
1.1 Definition of Alzheimer’s Pipeline Drugs
1.2 Alzheimer’s Pipeline Drugs Segment by Type
1.2.1 Global Alzheimer’s Pipeline Drugs Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Namenda
1.2.3 Ebixa
1.2.4 Axura
1.2.5 Aricept
1.2.6 Nootropil
1.2.7 Exelon
1.2.8 Memary
1.2.9 Solanezumab
1.2.10 LuAe58054
1.3 Alzheimer’s Pipeline Drugs Segment by Applications
1.3.1 Global Alzheimer’s Pipeline Drugs Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global Alzheimer’s Pipeline Drugs Overall Market
1.4.1 Global Alzheimer’s Pipeline Drugs Revenue (2014-2025)
1.4.2 Global Alzheimer’s Pipeline Drugs Production (2014-2025)
1.4.3 North America Alzheimer’s Pipeline Drugs Status and Prospect (2014-2025)
1.4.4 Europe Alzheimer’s Pipeline Drugs Status and Prospect (2014-2025)
1.4.5 China Alzheimer’s Pipeline Drugs Status and Prospect (2014-2025)
1.4.6 Japan Alzheimer’s Pipeline Drugs Status and Prospect (2014-2025)
1.4.7 Southeast Asia Alzheimer’s Pipeline Drugs Status and Prospect (2014-2025)
1.4.8 India Alzheimer’s Pipeline Drugs Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Alzheimer’s Pipeline Drugs
2.3 Manufacturing Process Analysis of Alzheimer’s Pipeline Drugs
2.4 Industry Chain Structure of Alzheimer’s Pipeline Drugs

3 Development and Manufacturing Plants Analysis of Alzheimer’s Pipeline Drugs
3.1 Capacity and Commercial Production Date
3.2 Global Alzheimer’s Pipeline Drugs Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Alzheimer’s Pipeline Drugs
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Alzheimer’s Pipeline Drugs Production and Capacity Analysis
4.2 Alzheimer’s Pipeline Drugs Revenue Analysis
4.3 Alzheimer’s Pipeline Drugs Price Analysis
4.4 Market Concentration Degree

5 Alzheimer’s Pipeline Drugs Regional Market Analysis
5.1 Alzheimer’s Pipeline Drugs Production by Regions
5.1.1 Global Alzheimer’s Pipeline Drugs Production by Regions
5.1.2 Global Alzheimer’s Pipeline Drugs Revenue by Regions
5.2 Alzheimer’s Pipeline Drugs Consumption by Regions
5.3 North America Alzheimer’s Pipeline Drugs Market Analysis
5.3.1 North America Alzheimer’s Pipeline Drugs Production
5.3.2 North America Alzheimer’s Pipeline Drugs Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Alzheimer’s Pipeline Drugs Import and Export
5.4 Europe Alzheimer’s Pipeline Drugs Market Analysis
5.4.1 Europe Alzheimer’s Pipeline Drugs Production
5.4.2 Europe Alzheimer’s Pipeline Drugs Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Alzheimer’s Pipeline Drugs Import and Export
5.5 China Alzheimer’s Pipeline Drugs Market Analysis
5.5.1 China Alzheimer’s Pipeline Drugs Production
5.5.2 China Alzheimer’s Pipeline Drugs Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Alzheimer’s Pipeline Drugs Import and Export
5.6 Japan Alzheimer’s Pipeline Drugs Market Analysis
5.6.1 Japan Alzheimer’s Pipeline Drugs Production
5.6.2 Japan Alzheimer’s Pipeline Drugs Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Alzheimer’s Pipeline Drugs Import and Export
5.7 Southeast Asia Alzheimer’s Pipeline Drugs Market Analysis
5.7.1 Southeast Asia Alzheimer’s Pipeline Drugs Production
5.7.2 Southeast Asia Alzheimer’s Pipeline Drugs Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Alzheimer’s Pipeline Drugs Import and Export
5.8 India Alzheimer’s Pipeline Drugs Market Analysis
5.8.1 India Alzheimer’s Pipeline Drugs Production
5.8.2 India Alzheimer’s Pipeline Drugs Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Alzheimer’s Pipeline Drugs Import and Export

6 Alzheimer’s Pipeline Drugs Segment Market Analysis (by Type)
6.1 Global Alzheimer’s Pipeline Drugs Production by Type
6.2 Global Alzheimer’s Pipeline Drugs Revenue by Type
6.3 Alzheimer’s Pipeline Drugs Price by Type

7 Alzheimer’s Pipeline Drugs Segment Market Analysis (by Application)
7.1 Global Alzheimer’s Pipeline Drugs Consumption by Application
7.2 Global Alzheimer’s Pipeline Drugs Consumption Market Share by Application (2014-2019)

8 Alzheimer’s Pipeline Drugs Major Manufacturers Analysis
8.1 Forest Laboratorie
8.1.1 Forest Laboratorie Alzheimer’s Pipeline Drugs Production Sites and Area Served
8.1.2 Forest Laboratorie Product Introduction, Application and Specification
8.1.3 Forest Laboratorie Alzheimer’s Pipeline Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Eisai
8.2.1 Eisai Alzheimer’s Pipeline Drugs Production Sites and Area Served
8.2.2 Eisai Product Introduction, Application and Specification
8.2.3 Eisai Alzheimer’s Pipeline Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 H. Lundbeck A/S
8.3.1 H. Lundbeck A/S Alzheimer’s Pipeline Drugs Production Sites and Area Served
8.3.2 H. Lundbeck A/S Product Introduction, Application and Specification
8.3.3 H. Lundbeck A/S Alzheimer’s Pipeline Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Novartis
8.4.1 Novartis Alzheimer’s Pipeline Drugs Production Sites and Area Served
8.4.2 Novartis Product Introduction, Application and Specification
8.4.3 Novartis Alzheimer’s Pipeline Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Merz GmbH & Co. KGaA
8.5.1 Merz GmbH & Co. KGaA Alzheimer’s Pipeline Drugs Production Sites and Area Served
8.5.2 Merz GmbH & Co. KGaA Product Introduction, Application and Specification
8.5.3 Merz GmbH & Co. KGaA Alzheimer’s Pipeline Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Johnson & Johnson
8.6.1 Johnson & Johnson Alzheimer’s Pipeline Drugs Production Sites and Area Served
8.6.2 Johnson & Johnson Product Introduction, Application and Specification
8.6.3 Johnson & Johnson Alzheimer’s Pipeline Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 UCB
8.7.1 UCB Alzheimer’s Pipeline Drugs Production Sites and Area Served
8.7.2 UCB Product Introduction, Application and Specification
8.7.3 UCB Alzheimer’s Pipeline Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served

9 Development Trend of Analysis of Alzheimer’s Pipeline Drugs Market
9.1 Global Alzheimer’s Pipeline Drugs Market Trend Analysis
9.1.1 Global Alzheimer’s Pipeline Drugs Market Size (Volume and Value) Forecast 2019-2025
9.2 Alzheimer’s Pipeline Drugs Regional Market Trend
9.2.1 North America Alzheimer’s Pipeline Drugs Forecast 2019-2025
9.2.2 Europe Alzheimer’s Pipeline Drugs Forecast 2019-2025
9.2.3 China Alzheimer’s Pipeline Drugs Forecast 2019-2025
9.2.4 Japan Alzheimer’s Pipeline Drugs Forecast 2019-2025
9.2.5 Southeast Asia Alzheimer’s Pipeline Drugs Forecast 2019-2025
9.2.6 India Alzheimer’s Pipeline Drugs Forecast 2019-2025
9.3 Alzheimer’s Pipeline Drugs Market Trend (Product Type)
9.4 Alzheimer’s Pipeline Drugs Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Alzheimer’s Pipeline Drugs Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer



【掲載企業】

Forest Laboratorie、Eisai、H. Lundbeck A/S、Novartis、Merz GmbH & Co. KGaA、Johnson & Johnson、UCB

★調査レポート[世界のアルツハイマー病のパイプライン薬市場 2019年] (コード:QYR20FB00357)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のアルツハイマー病のパイプライン薬市場 2019年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆